Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pramipexole Augmentation in the Treatment of Unipolar and Bipolar Depression: A Retrospective Chart Review

Pramipexole Augmentation in the Treatment of Unipolar and Bipolar Depression: A Retrospective... Objective: To assess the effectiveness and safety of pramipexole as an adjunctive medication in refractory bipolar and unipolar depression in a naturalistic setting. Methods: Retrospective chart review by psychiatrists on staff at a university hospital identified all patients who had received pramipexole. Response was based on moderate to marked improvement in the Clinical Global Impression-Improvement (CGI-I) scale. Results: Pramipexole (mean dose 0.70 mg/d, mean duration 24.4 weeks) was effective in 6/12 (50.0%) of patients with bipolar depression, and 8/20 (40%) of patients with unipolar depression, mean duration of follow-up of 24.4 weeks. One case of transient hypomania was noted. Eight patients discontinued pramipexole due to lack of response and four due to side effects. Conclusions: Pramipexole, used as an adjunct to antidepressants or mood stabilizers, appeared to be effective and safe in the treatment of unipolar and bipolar depression. These uncontrolled, retrospective, naturalistic pilot data require confirmation by controlled research before conclusions can be made. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Pramipexole Augmentation in the Treatment of Unipolar and Bipolar Depression: A Retrospective Chart Review

Download PDF
4 pages

Loading next page...
 
/lp/springer-journals/pramipexole-augmentation-in-the-treatment-of-unipolar-and-bipolar-MFI4Sdn0zB
Publisher
Springer Journals
Copyright
Copyright © 2000 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1009060800999
Publisher site
See Article on Publisher Site

Abstract

Objective: To assess the effectiveness and safety of pramipexole as an adjunctive medication in refractory bipolar and unipolar depression in a naturalistic setting. Methods: Retrospective chart review by psychiatrists on staff at a university hospital identified all patients who had received pramipexole. Response was based on moderate to marked improvement in the Clinical Global Impression-Improvement (CGI-I) scale. Results: Pramipexole (mean dose 0.70 mg/d, mean duration 24.4 weeks) was effective in 6/12 (50.0%) of patients with bipolar depression, and 8/20 (40%) of patients with unipolar depression, mean duration of follow-up of 24.4 weeks. One case of transient hypomania was noted. Eight patients discontinued pramipexole due to lack of response and four due to side effects. Conclusions: Pramipexole, used as an adjunct to antidepressants or mood stabilizers, appeared to be effective and safe in the treatment of unipolar and bipolar depression. These uncontrolled, retrospective, naturalistic pilot data require confirmation by controlled research before conclusions can be made.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 8, 2004

References

  • The behavioural effects of pramipexole, a novel dopamine receptor agonist
    Maj, J; Rogoz, Z; Skuza, G; Kolodziejczyk, K
  • Antidepressant effects of pramipexole, a novel dopamine receptor agonist
    Maj, J; Rogoz, Z; Skuza, G; Kolodziejczyk, K
  • The mesolimbic dopamine system as a target for rapid antidepressant action
    Willner, P
  • Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
    Corrigan, MH; Denahan, AQ; Wright, EC; Ragual, RJ; Evans, DL
  • Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease
    Piercey, MF
  • Pramipexole, a dopamine agonist, in major depression: Antidepressant effects and tolerability in an open-label study with multiple doses
    Szegedi, A; Hillert, A; Wetzel, H; Klieser, E; Gaebel, W; Benkert, O
  • Pramipexole in refractory bipolar depression
    Goldberg, J; Frye, M; Dunn, R
  • Toward a new paradigm in the treatment of Parkinson's disease
    Oertel, W
  • The effects of dopaminergic D2 stimulation and blockade on smoking behavior
    Caskey, NH; Jarvik, ME; Wirshing, WC
  • Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
    Frucht, S; Rogers, JD; Greene, PE; Gordon, MF; Fahn, S